Praxis Precision Medicines, Inc. Stock Price, News & Analysis

Praxis Precision Medicines (NASDAQ: PRAX) announced a proposed public offering of its common stock and, for certain investors, prefunded warrants to buy common stock. The company said all offered securities will be sold by Praxis and underwriters have a 30-day option to buy additional shares up to 15% of the offering. TD Cowen, Piper Sandler, Guggenheim Securities and Truist Securities are joint book-running managers. The offering is made from a shelf registration that became effective on Dec 23, 2024 and is subject to market and customary closing conditions. Final terms will appear in a prospectus supplement; the release is not an offer to sell securities.

Praxis Precision Medicines (NASDAQ: PRAX) reported positive topline Phase 3 results for ulixacaltamide in the Essential3 program for essential tremor (ET) on October 16, 2025. In Study 1 (parallel-group) ulixacaltamide produced a mean Modified Activities of Daily Living-11 improvement of 4.3 points at Week 8 (p<0.0001) and all key secondaries were statistically significant (p<0.001). Study 2 (randomized-withdrawal) met its primary endpoint (maintenance of effect, p=0.0369) and a key secondary (rate of improvement, p=0.0042). The drug was generally well tolerated with no drug-related serious adverse events. Praxis has requested a pre-NDA meeting with the FDA and will host an investor call on October 16, 2025.

Praxis Precision Medicines (Nasdaq: PRAX) announced on October 1, 2025 that its Compensation Committee granted restricted stock unit awards covering an aggregate of 4,200 shares to three new non‑executive employees under the 2024 Inducement Plan.

The awards were granted as inducements material to the employees entering employment in accordance with Nasdaq Listing Rule 5635(c)(4). The restricted stock units will vest in four equal annual installments, subject to the recipients' continued employment on each vesting date. The 2024 Inducement Plan is reserved exclusively for equity awards to newly hired individuals or those returning after a bona fide break in service.

ReCode Therapeutics has secured over $29 million in additional financing to advance its genetic medicines pipeline. The company received $3 million in new funding from the Cystic Fibrosis Foundation, bringing the Foundation's total potential investment to $33 million for mRNA and gene editing research programs.

The company announced a research collaboration with Praxis Precision Medicines (NASDAQ: PRAX) to develop lipid nanoparticle formulations for ASO delivery to the brain. ReCode's lead program, RCT2100, an inhaled mRNA therapy for cystic fibrosis, is currently in Phase 2 clinical trials, aiming to benefit all CF patients, including those with rare and nonsense mutations.

Praxis Precision Medicines (NASDAQ: PRAX), a clinical-stage biopharmaceutical company focused on CNS disorders, has announced its participation in three major investor conferences in September 2025:

• Baird Global Healthcare Conference - Corporate presentation on September 9th at 9:00 AM EDT
• H.C. Wainwright Global Investment Conference - Fireside chat on September 10th at 8:30 AM EDT
• TD Cowen Novel Mechanisms Summit - Virtual presentation on September 18th at 3:00 PM EDT

One-on-one meetings will be available at all events, and webcasted presentations will be accessible through the company's website for 90 days.

Praxis Precision Medicines (NASDAQ: PRAX), a clinical-stage biopharmaceutical company focused on CNS disorders, has granted 6,238 restricted stock units to eight new non-executive employees under its 2024 Inducement Plan. The grants, approved by the Compensation Committee on September 2, 2025, were made in accordance with Nasdaq Listing Rule 5635(c)(4).

The restricted stock units will vest over four equal annual installments, contingent upon continued employment. These equity awards are specifically designed for new hires who were not previously Praxis employees, serving as employment inducements.

Praxis Precision Medicines (NASDAQ: PRAX), a clinical-stage biopharmaceutical company focused on developing CNS disorder therapies, has announced an upcoming virtual fireside chat. CEO Marcio Souza will participate in a discussion with TD Cowen's Biotechnology Analyst Ritu Baral on September 2, 2025, at 10:00 AM EST.

The discussion will focus on Praxis' recent presentations at the 36th International Epilepsy Consortium (IEC). The company specializes in developing treatments for central nervous system disorders characterized by neuronal excitation-inhibition imbalance.

Praxis Precision Medicines (NASDAQ: PRAX) will present extensive clinical and preclinical data across its precision epilepsy pipeline at the 36th International Epilepsy Congress (IEC) 2025 in Lisbon from August 30 to September 3.

The company will deliver twelve presentations featuring updates on three key programs: Vormatrigine (RADIANT study topline results in focal onset seizures), Relutrigine (EMBOLD study in SCN2A/SCN8A-DEE and EMERALD study), and Elsunersen (EMBRAVE3 study and emergency use cases).

Presentations will take place across multiple sessions, including platform presentations and poster sessions, with the company maintaining presence at Booth #435.

Praxis Precision Medicines (NASDAQ:PRAX), a clinical-stage biopharmaceutical company focused on CNS disorders, has granted restricted stock unit (RSU) awards to three new non-executive employees. The awards, totaling 3,875 shares of common stock, were issued under the company's 2024 Inducement Plan on August 1, 2025.

The RSUs will vest over four equal annual installments, contingent on continued employment. These grants were made in accordance with Nasdaq Listing Rule 5635(c)(4) as inducement awards for new hires who were not previously Praxis employees.